What does UnitedHealth Group Incorporated (UNH) do?

What UnitedHealth Group Incorporated does, in one paragraph

UNH UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.

Beyond the headline: UNH sits in the Health Care sector, which materially shapes how we value it. Sector context drives the cost-of-equity inputs, the peer set, the appropriate terminal multiple, and the scenario-probability weights — applying generic defaults across sectors is one of the largest single sources of valuation error in retail-grade research, which is why our methodology is calibrated archetype by archetype rather than applied uniformly.

Why the mature compounder archetype matters for UNH

As a mature compounder, UNH's economic engine has a recognizable shape that downstream parameters lean into. Hyper-growth names get faster terminal-growth decay and longer explicit-window forecasts; mature compounders get tighter sensitivity bands and heavier weight on PEG-adjusted peer multiples; cyclicals get mid-cycle earnings normalization and capital-cycle-aware scenario weights; financials and REITs get sector-specific lenses (price-to-book / FFO) instead of generic DCF. The mature compounder classification is the most consequential single input to our model.

UNH's competitive moat at a glance

On the competitive-moat axis, UNH scores 9/10 in our framework. The moat headline from the full report: "Wide". The moat score and its source (network effects, switching costs, intangibles, scale, regulatory advantage, etc.) are documented in §4 of the canonical report; the durability of the moat — not just its current width — is what drives long-run economic profit and therefore long-run total return.

Where to read more on UNH

The canonical report at /stocks/unh/analysis is the deepest read: 14 sections covering executive summary, bear case (first), financial history, competitive moat, industry cycle, peer comparison, intrinsic valuation with sensitivity grids, scenario analysis, earnings decision tree, position management, three-investor perspectives, scorecard, and final recommendation. The /analysis/forecast tab focuses on the bull / base / bear price targets; /analysis/valuation walks through the model stack; /analysis/risks runs the full bear case in long form.

For readers who want to understand the methodology before reading any specific report, the public /methodology page documents the 9-phase framework end to end. The /independent-research page argues the positioning — the five testable promises every report carries.

Frequently asked questions